Shadow Play's  Instablog

Shadow Play
Send Message
I am just an ordinary investor looking out for family,friends and others at the same time. I try to invest in stocks that will pay me back handsomely for holding for long periods of time. I've been trading for twelve years and have achieved many goals in life by simply keeping it simple and that... More
  • Is Teva Thinking Of A Takeover? 2 comments
    Nov 28, 2012 10:06 PM | about stocks: ATRS

    This is from a friend on the YMB who always does his part to keep investors informed.He, Jab9, came across this and I wanted to share it with all of you.


    David Wainer in Tel Aviv and the editor responsible for this story: Phil Serafino.

    Teva to Focus on Smaller M&A


    Teva Pharmaceutical Industries Ltd. is shifting away from the multi-billion dollar acquisitions that have defined its growth for the past decade, indicating acquisitions don't have to be major to be important," said Chairman Phillip Frost, who owns about $815 million of Teva shares, in an interview on November 19 in his Miami office. "The idea of the multibillion-dollar type of acquisition is going to be reserved for very special cases going forward, in which the desirability is so compelling and so game-changing that everyone will feel it has to be done."

    Mr. Frost's comments signal the world's biggest generic drugmaker may be shying from a strategy that saw it buy Frazer, Pennsylvania-based Cephalon Inc. for $6.2 billion, and Ratiopharm GmbH, based in Ulm, Germany, in a $4.9-billion deal. Petach Tikva, Israel-based Teva has made 25 buy-outs in the past 10 years, including five valued at $3 billion or more, according to data compiled by Bloomberg.

    The company's Israeli shares gained 1.6% to 155.60 shekels, the equivalent of $39.84, in Tel Aviv. The benchmark TA-25 index rose 0.3% to 1,208.66. Teva's New York shares climbed 1.8% recently, leading gains in the Bloomberg Israel-US Equity Index of the largest Israeli companies traded in New York.

    "There is the opportunity for product acquisitions, for small company acquisitions, for technology acquisitions, and to bring in new people who themselves are capable of creating the new products," explained Mr. Frost.

    Teva's board tapped earlier this year Jeremy Levin, a former Senior Vice President for Strategy at Bristol-Myers Squibb Co., to become the Chief Executive Officer of the world's largest maker of generic medicines, as it seeks to diversify in branded drugs. The CEO, who joined the company in May, plans to give investors a strategy update, dubbed "Project Spring," on December 11 in New York.

    American depositary receipts of the Petach Tikva, Israel-based company have dropped 2.2% this year, lagging behind the 8.3% rally for the MSCI World Pharmaceutical Index (MXWD0PH), as investors remain skeptical the company can sustain growth for its branded multiple-sclerosis drug Copaxone. Teva's ADRs trade at 7.3 times estimated earnings, the lowest valuation among the world's 20 biggest drug companies, which have an average price-earnings ratio of 13.4.

    Teva's stock is undervalued, and investors will realize that as Mr. Levin implements a new strategy, said Mr. Frost, who became a Teva shareholder when he sold his generic-drug maker Ivax Corp. to Teva for $7.6 billion in 2006.

    "On the novel product side, Jeremy brings experience to the table that we didn't really have at Teva before," he said. Mr. Levin and Michael Hayden, Teva's new Chief Scientific Officer, "will have their influence permeate the company so that the mindset will over time shift from being a generic company to a more broadly based pharmaceutical business," said Mr. Frost. "Copaxone sales will hold up."

    The drug, an injection that accounts for about 40% of US sales of MS treatments, faces new competition from Novartis AG oral drug Gilenya. US regulators are reviewing another MS pill, Biogen Idec Inc. BG-12. Generic-drug makers are also appealing a court decision that upheld Copaxone's US patents through 2015.

    "Copaxone will be around for quite a while, I'm sure of it," stressed Mr. Frost. "At a certain point, it's possible a generic will affect certain markets, but the product itself will continue to be important in other markets."

    The US court decision may give Teva more time to switch patients to a new, higher-dose version of the drug. Teva has said that a late-stage trial of a longer-acting formulation reduced MS relapses more than a placebo and showed a "favorable" safety profile. Teva is also considering an entrance into emerging markets from Brazil to China, where the company's presence is relatively smaller, said Mr. Frost.

    "There is room for a lot of creativity at this point," said Mr. Frost. "The creativity will go along with experience."

    This makes for a good case for Teva to think about a merger or takeover of Antares (NASDAQ:ATRS).It would make perfect sense being both have a long and strong working relationship.

    Disclosure: I am long ATRS.

    Stocks: ATRS
Back To Shadow Play's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (2)
Track new comments
  • jab91252
    , contributor
    Comments (16) | Send Message


    The article you noted and posted is attributed to the publication, "Drug Development and Delivery" and as you noted the reporter, David Wainer and the Editor, Phil Serafino. And anyone interested in developments in the latest delivery methods, drugs and developments would do themselves well to subscribe by simply signing up. In fact the digital subscription is free and no, I am no affiliated with them, just an individual investor like you and so many others. It is a great source to gleem information and this particular article is just one example.


    The publication has in the past, ran articles featuring Antares. In particular, I recall an article featuring Antares/TEVA's successful collaborative, TEV-TROPIN for Human Growth Hormone wherein TEVA increased sales as a result of using Antares proprietary injector, substantially.


    One of the main objectives of Antares injector platform(s) is to make using injectors, patient friendly, quick and painless. The current, as you know, partnership between Antares and TEVA is alive and doing well. The EpiPen litigation between King Pharma/Pfizer, et al and TEVA has been settled and Antares will begin receiving orders from TEVA during yr(s) 2013 and 2014, prior to the date certain launch of TEVA's generic EpiPen version in Mid 2015.


    Antares, as you've noted before, is embarking on their own proprietary drug/injector combo of MTX (methotrexate) - set to be filed soon with the FDA for a NDA. After that, its QS-T, for low testosterone, again, Antares own proprietary drug/injector combo and Antares has targeted one if not more drugs for "in-house" commercialization using their novel injectors.


    This all (and more than I noted) begs the question, can Teva Pharmaceutical, Inc NOT be grooming Antares for the future?


    29 Nov 2012, 02:23 AM Reply Like
  • lokodude
    , contributor
    Comments (210) | Send Message
    Hi Shadow, I was doing my Anatres search this morning and i found your article. I did not know you wrote this article, and a fine job you did. I am glad you are finally coming to a conclusion I expressed a long time ago and have been continually providing news related to my view of the ATRS/Teva/Sicor world.


    I suggest your readers search for Teva/Sicor on the YMB I have been providing links to relevant documents for months on the potential purchase of ATRS by Teva. It is obvious to any serious investor that takes their DD serious.


    Also since you mention Copaxone, I think your readers should consider what I have been preaching (pun intended) for months on the new 20 and 40 mg regime that Teva is pushing to keep some control of Copaxone.


    Here is my post n Nicks site yesterday, for your readers....


    Hey Nick Chiu, what can I say.....Wow, all of that and you did not even provide your readers with a clue as to the future of Copaxone. Something a couple of my good buddies on the YMB site, do all the time. They ramble on with a good story about the obvious, and then do not provide their readers with insight into future. Lacking insight and confidence in their calls I guess, which is why I like articles from, StockLasser, who does a fine job of giving readers something to think about and dig into, tho I have found him wrong on occasions. But who isn't? So as I generously do, with out pay, for Scott's readers, let me give your readers the abbreviated 100% non-speculative future for Copaxone.


    If you and your readers will look at the clinical trials you will see there are a number of specific 20 and 40 mg trials. The trials were conducted for two new therapy methods, the Reduced Volume, (20mg/0.5ml) and reduced 3XW 40mg/1.0 ml injection. Teva is preparing a new FDA filing for the 3XW 40mg/1.0 copaxone early next year, AND it will use Antares Two-Stage Reconstituting Injector. There is one more trial for each of the 2 methods that needs to be conducted and of course, those are the final trials using the New injectors, and that is when the world will know, "The rest of the story"......




    Teva/Antares will also be using the the Vibex QS for the new 20mg/0.5ml method....




    Believe me or not, the story is out there....... I have tired discussing it on the YMB, site, so if your readers search for Copaxone on ATRS YMB, they will find a lot of good info to begin their own DD.


    The sweet thing, is that we will all know on or before the Dec 11, Investor meeting, as has been repeatedly mentioned by Teva these past few weeks. So start digging investors....into ANtares Pharma that is..... BECAUSE that is where the money will be made. There is a lot more on ATRS, but your story was on Copaxone, so I did not mention Lonquex, Balugrastim, Neutroval, or the Follitropin ANDA filling.


    Later, LD


    This is one of the LD-Teva/Sicor posts to get you started.

    5 Dec 2012, 09:06 AM Reply Like
Full index of posts »
Latest Followers


  • $ATRS started as a buy by Jefferies
    Dec 19, 2012
  • I see $ATRS meditating from the 3.60's-4.10's until late January. Once the Vibex MTX filing comes to light with FDA, then it pushes to $5.
    Dec 11, 2012
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.